Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.36 |
| ▸ | MGAM | O43451 | 1/20 | 0.36 |
| ▸ | RXRA | P19793 | 10/20 | 0.35 |
| ▸ | RARB | P10826 | 4/20 | 0.34 |
| ▸ | RARG | P13631 | 3/20 | 0.34 |
| ▸ | RARA | P10276 | 2/20 | 0.34 |
| ▸ | P4HA1 | P13674 | 2/20 | 0.34 |
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.34 |
| ▸ | HCAR3 | P49019 | 4/20 | 0.34 |
| ▸ | RXRB | P28702 | 5/20 | 0.34 |
| ▸ | RXRG | P48443 | 5/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | MIF | P14174 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29746865 | 1.00 | HCAR2 (0.36) | HCAR2MGAMRXRARARBRARG | |
| SCHEMBL24401254 | 0.82 | MAPK1 (0.40) | L3MBTL1 | |
| SCHEMBL29746895 | 0.82 | MAPK1 (0.40) | L3MBTL1 | |
| SCHEMBL29027009 | 0.79 | CRBN (0.38) | — | |
| SCHEMBL30505940 | 0.79 | CRBN (0.38) | — | |
| SCHEMBL24401271 | 0.74 | ALDH1A1 (0.41) | HCAR2MGAMRARBRARAP4HA1 | |
| SCHEMBL29027055 | 0.73 | — | — | |
| SCHEMBL29027100 | 0.73 | HTT (0.31) | — | |
| SCHEMBL30505889 | 0.73 | HTT (0.31) | — | |
| SCHEMBL24401007 | 0.71 | KDM1A (0.58) | RXRARARBRARGRARARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220135539-A1 | BIARYL AMIDE COMPOUNDS, PREPARATION METHODS AND MEDICAL APPLICATIONS THEREOF | Eternity Bioscience Inc. | 2022-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135539-A1 | BIARYL AMIDE COMPOUNDS, PREPARATION METHODS AND MEDICAL APPLICATIONS THEREOF | BRAF, NRAS, RAF1 | HCAR2 2916/4885MGAM 2897/4885RXRA 712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.